Century Therapeutics, Inc.
IPSC
$0.51
-$0.02-3.63%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 113.34M | 114.13M | 114.90M | 6.59M | 2.69M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 113.34M | 114.13M | 114.90M | 6.59M | 2.69M |
| Cost of Revenue | 105.34M | 110.04M | 110.40M | 107.24M | 100.17M |
| Gross Profit | 8.00M | 4.09M | 4.50M | -100.65M | -97.48M |
| SG&A Expenses | 32.16M | 33.68M | 34.18M | 34.51M | 33.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 137.50M | 143.72M | 144.58M | 141.76M | 134.16M |
| Operating Income | -24.16M | -29.59M | -29.68M | -135.17M | -131.47M |
| Income Before Tax | -24.70M | -21.51M | -20.16M | -124.78M | -130.75M |
| Income Tax Expenses | 1.78M | 1.77M | 1.79M | 1.79M | -854.00K |
| Earnings from Continuing Operations | -26.48 | -23.28 | -21.95 | -126.57 | -129.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.48M | -23.28M | -21.95M | -126.57M | -129.89M |
| EBIT | -24.16M | -29.59M | -29.68M | -135.17M | -131.47M |
| EBITDA | -11.29M | -16.55M | -16.38M | -121.86M | -117.93M |
| EPS Basic | -0.31 | -0.28 | -0.28 | -1.62 | -1.86 |
| Normalized Basic EPS | -0.11 | -0.14 | -0.14 | -0.98 | -1.03 |
| EPS Diluted | -0.31 | -0.28 | -0.28 | -1.62 | -1.86 |
| Normalized Diluted EPS | -0.11 | -0.14 | -0.14 | -0.98 | -1.03 |
| Average Basic Shares Outstanding | 344.14M | 342.38M | 338.23M | 314.51M | 289.09M |
| Average Diluted Shares Outstanding | 344.21M | 342.45M | 338.31M | 314.51M | 289.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |